Els Van Nieuwenhuysen

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Ignace Vergote, Antonio González‐Martín, Keiichi Fujiwara et al. · New England Journal of Medicine · 2024 · 159 citations · Full text

Medicine, Gynecology, Oncology +16

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote, Els Van Nieuwenhuysen, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.

Domenica Lorusso, Ignace Vergote, Roisin E. O’Cearbhaill et al. · Journal of Clinical Oncology · 2022 · 22 citations

Pharmacy, Oncology, Pharmacotherapy +17

LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Annals of Oncology · 2023 · 12 citations · Full text

Medicine, Oncology, Pharmacology +9